NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report)’s stock price was up 7.1% on Monday . The stock traded as high as $15.21 and last traded at $15.15. Approximately 388,634 shares changed hands during trading, a decline of 56% from the average daily volume of 886,004 shares. The stock had previously closed at $14.14. Analyst Ratings […]
NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price decreased by equities research analysts at Needham & Company LLC from $24.00 to $19.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s price target indicates […]
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) shares dropped 7.7% on Tuesday after Needham & Company LLC lowered their price target on the stock from $24.00 to $19.00. Needham & Company LLC currently has a buy rating on the stock. NeoGenomics traded as low as $13.70 and last traded at $14.05. Approximately 252,873 shares changed […]
NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus EPS estimate of -0.010. The company issued revenue guidance of $650.0 million-$660.0 million, compared to the consensus revenue estimate of $654.6 million. Analyst Upgrades and Downgrades NEO […]
NeoGenomics (NASDAQ:NEO – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus EPS estimate of -0.010. The company issued revenue guidance of $650.0 million-$660.0 million, compared to the consensus revenue estimate of $654.6 million. Analyst […]